Patent echoes for Viralytics
Monday, 30 March, 2009
Sydney company Viralytics has received a patent in the US for its range of echoviruses, which aim to bind to and infect cancer cells.
The echovirus type 1 (EV1) binds to cells expressing integrin alpha2 beta 2, a receptor on the cell surface receptor highly expressed in some cancers, particularly prostate, ovarian and gastric tumours.
Viralytics has a proprietary formulation of EV1 called Evatak, as well as a formulation for a subset of coxsackie A viruses called Cavatak. Cavatak binds to the receptors intercellular adhesion molecule-1 and decay accelerating factor.
The company is running Phase I trials of Cavatak in melanoma, prostate, breast and head and neck cancers.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
